Targeted Immunotherapy Is Redefining What High-Risk Means in Adult B-Cell Leukemia

Adult B-cell acute lymphoblastic leukemia (B-ALL) has long been sorted into risk groups using a short list of clinical and cytogenetic features: older age, a high white cell count at diagnosis, and the presence of the Philadelphia chromosome. A new review published in Blood Research argues that this framework is breaking down. With next-generation tyrosine kinase inhibitors, bispecific T-cell engagers, antibody–drug conjugates, and chimeric antigen receptor (CAR) T cells now woven into frontline treatment, some historically ominous features have lost much of their predictive weight, while a set of molecularly defined subgroups continues to carry a stubbornly poor prognosis.

The clearest example of this shift is Philadelphia chromosome (Ph)-positive ALL, once among the poorest-risk subtypes of adult leukemia. Before tyrosine kinase inhibitors existed, long-term survival was largely confined to patients eligible for allogeneic hematopoietic cell transplantation. The D-ALBA study, which combined dasatinib with the CD19-directed bispecific antibody blinatumomab, reported durable remissions with 4-year disease-free survival of 75.8%, overall survival of 80.7%, and event-free survival of 74.6%. A phase 2 study of ponatinib plus blinatumomab in newly diagnosed patients went further, with complete molecular response rates above 85% and estimated 3-year event-free and overall survival of roughly 77% and 91%. On the strength of such results, the review’s author argues that Ph positivity alone may no longer uniformly signal high-risk disease.

Biology, however, still matters within Ph-positive ALL. The IKZF1plus genotype—defined as deletion of IKZF1 together with additional deletions of CDKN2A/B and/or PAX5—marks a subset at increased risk of relapse and treatment failure. In the long-term D-ALBA analysis, patients with IKZF1plus had a 4-year disease-free survival of only 45.5%, compared with 82.3% for those without IKZF1 deletion and 74.0% for those with IKZF1 deletion alone. In adults treated with hyper-CVAD plus dasatinib or ponatinib, IKZF1plus was found in 46% of patients and remained an independent predictor of inferior overall survival in multivariable analysis. Notably, updated genomic analyses of the ponatinib–blinatumomab regimen suggest IKZF1plus is no longer significantly associated with increased relapse risk in that setting, although longer follow-up and prospective validation are still needed.

Hypodiploid leukemia presents a different picture. Defined by a modal chromosome number below 44, it splits into near-haploid disease (24–31 chromosomes), often driven by Ras signaling and receptor tyrosine kinase alterations, and low-hypodiploid disease (32–39 chromosomes), strongly tied to TP53 alterations and genomic instability. Comprehensive molecular analyses indicate that biallelic TP53 inactivation is present in more than 90% of adult low-hypodiploid cases, and the disease appears to arise from age-related TP53-mutant clonal hematopoiesis. Unlike pediatric cases, where germline TP53 changes are relatively common, adult mutations are predominantly somatic and often precede leukemic transformation, suggesting TP53 dysfunction is a central driver rather than a secondary passenger.

TP53 mutations also occur across other genetic subtypes of adult B-ALL. In a contemporary multicenter study of more than 800 adults, TP53-mutated disease was associated with significantly inferior overall survival compared with TP53-wild-type disease, independently of other prognostic variables, and biallelic alterations carried particularly poor outcomes. Encouragingly, retrospective analyses suggest that blinatumomab, inotuzumab ozogamicin, and CD19-directed CAR T cells can achieve clinically meaningful responses despite TP53 alterations—plausibly because immune-based killing acts independently of p53-mediated apoptotic pathways that underlie chemoresistance. Durable disease control, however, remains difficult.

Two further subgroups resist reclassification. Ph-like ALL, which mimics the gene-expression profile of Ph-positive disease without the BCR::ABL1 fusion, occurs in roughly 20%–30% of adults with B-ALL and shows lower rates of measurable residual disease (MRD) clearance, higher relapse rates, and inferior survival. Its genomic heterogeneity—about half of cases carry CRLF2 rearrangements, 10%–20% harbor ABL-class fusions, and alterations in EPOR, JAK2, FLT3, and NTRK also occur—complicates diagnosis, which still relies on specialized gene-expression profiling or stepwise algorithms combining flow cytometry, fluorescence in situ hybridization, and sequencing. Kinase-targeted therapy shows promising preclinical activity but lacks prospective clinical validation, while a post hoc analysis of the phase III TOWER trial found blinatumomab produced higher remission rates and longer survival than chemotherapy in relapsed or refractory Ph-like disease. KMT2A-rearranged ALL, found in 5%–10% of adult cases and most commonly involving the KMT2A::AFF1 fusion, likewise shows inferior long-term survival even after MRD-negative remission, supporting an intrinsically aggressive biology.

Running through the review is the argument that risk assessment must become dynamic rather than fixed at diagnosis. MRD after induction and consolidation is among the strongest predictors of relapse and survival in adult ALL, independent of baseline genetic features, and persistent MRD can reclassify genetically standard patients as functionally high risk. Assay sensitivity matters: flow cytometry detects disease at roughly 10–4, while molecular and next-generation sequencing assays reach 10–5 to 10–6, and the European LeukemiaNet recommends decisions based on MRD negativity rely on testing at a sensitivity of at least 0.01%. The ECOG-ACRIN E1910 trial sharpened the point: among adults with Ph-negative B-ALL who were already MRD-negative by flow cytometry, adding blinatumomab to consolidation raised 3-year overall survival from 68% to 85% and relapse-free survival from 64% to 80%. MRD negativity, in other words, does not mean eradication, and high-sensitivity sequencing around transplantation may identify residual disease that flow cytometry misses.

The frontline data accumulating for immunotherapy-based regimens underline why early integration is gaining favor. In a multicenter study of adults with TP53-mutated ALL, frontline blinatumomab-based regimens produced complete response rates above 90% in newly diagnosed patients, with roughly 80%–90% achieving MRD-negative remission. A phase 2 study of sequential hyper-CVAD and blinatumomab in newly diagnosed Ph-negative ALL—including 21 of 38 patients with at least one high-risk feature—yielded estimated 3-year relapse-free and overall survival of 73% and 81%. And in older patients treated with mini-hyper-CVD plus inotuzumab ozogamicin followed by blinatumomab, a cohort in which about 40% carried TP53 mutations, the regimen achieved a 99% rate of complete remission or remission with incomplete hematologic recovery, a 94% MRD-negativity rate, and estimated 5-year progression-free and overall survival of 44% and 46%.

These advances come with new failure modes. Under selective pressure from blinatumomab or CD19-directed CAR T cells, leukemic cells can evade treatment through loss or reduction of CD19 expression via genetic alteration, alternative splicing, or expansion of preexisting CD19-negative clones; inotuzumab can similarly select subclones with dim or absent CD22. Lineage switch, particularly in KMT2A-rearranged disease, allows clones to acquire a myeloid phenotype while retaining the founding alteration, and extramedullary sites including the central nervous system can relapse despite systemic remission. These patterns argue for serial monitoring of target-antigen expression, molecular MRD, and extramedullary disease throughout treatment.

The practical consequence is a recalibrated role for transplantation. Routine allogeneic transplantation for every patient with Ph-positive ALL is increasingly being reconsidered given ponatinib–blinatumomab outcomes, though IKZF1plus patients with suboptimal molecular responses may still benefit. Transplantation remains a reasonable consolidation for eligible TP53-mutated patients, continues to be recommended in first remission for transplant-eligible KMT2A-rearranged disease, and remains an important option in Ph-like ALL where long-term evidence for targeted approaches is limited. Whether to transplant after CAR T-cell therapy should be individualized, guided by early B-cell recovery, loss of CAR T-cell persistence, recurrent MRD, or adverse genomics. The review’s bottom line: high-risk classification in adult B-ALL should now reflect biological drivers of resistance and continuously updated treatment response, not traditional cytogenetic categories alone—and prospective studies are still needed to determine how best to integrate these tools.

Subject of Research: How targeted immunotherapy is changing the definition of high-risk adult B-cell acute lymphoblastic leukemia

Article Title: High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy

Article References: Baek, D. W. (2026). High-risk features in adult patients with B-cell acute lymphoblastic leukemia: redefining risk in the era of targeted immunotherapy. Blood Research, 61(1), Article 55. https://doi.org/10.1007/s44313-026-00175-w

Image Credits: AI Generated

DOI: 10.1007/s44313-026-00175-w

Keywords: B-cell acute lymphoblastic leukemia, Philadelphia chromosome, IKZF1plus, TP53 mutation, Ph-like ALL, KMT2A rearrangement, blinatumomab, inotuzumab ozogamicin, ponatinib, measurable residual disease, allogeneic hematopoietic cell transplantation, CAR T-cell therapy